Calcium Channels
The CACNA1A gene encodes the alpha-1A subunit of the CaV2.1 P/Q-type voltage-gated calcium channel, controlling neurotransmitter release in brain neurons.
Standing together to fund personalized genetic medicine (ASO therapy) for Archie’s rare CACNA1A gene mutation, paving the way for rare disease breakthroughs.
“Put on all of God’s armor so that you will be able to stand firm…”
Ephesians 6:11
Custom oligonucleotide therapy (ASO) developed by the n-Lorem Foundation gives Archie a chance for a healthier future.
Every parent expects challenges, but nothing prepares you to hear that a single letter in your child’s DNA is changed.
Spirited, resilient, and smiling through neurological therapy appointments and lab evaluations.
“Archie lights up every room he enters. His laughter reminds us why we fight so hard every single day to give him the treatment he deserves.”
The Family
From early infancy, Archie showed subtle developmental delays and unexpected neurological symptoms. After months of medical testing, consultations with specialists, and whole genome sequencing, we received the diagnosis: Archie has a rare, de novo mutation in the CACNA1A gene.
The CACNA1A gene provides instructions for making a key subunit of the CaV2.1 calcium channel, vital for normal communication between brain cells. Archie’s specific variant disrupts this delicate signaling pathway, leading to challenges with motor function, speech, and potential seizure activity.
Archie’s single nucleotide change requires targeted personalized medicine rather than standard off-the-shelf pharmaceuticals.
Working with the n-Lorem Foundation to design a custom antisense oligonucleotide (ASO) to silence or correct the faulty gene copy.
We created Archie’s Armor to rally family, friends, and supporters around Archie’s journey. Just as armor protects in battle, our mission is to wrap Archie in love, spiritual strength, cutting-edge medical science, and financial support for his personalized treatment program.
What is the CACNA1A gene, how does it function, and why are targeted genetic therapies so transformational?
The CACNA1A gene encodes the alpha-1A subunit of the CaV2.1 P/Q-type voltage-gated calcium channel, controlling neurotransmitter release in brain neurons.
Mutations can be “gain-of-function” (an overactive channel) or “loss-of-function” (an underactive channel). Identifying Archie’s exact variant is key to tailoring treatment.
Antisense oligonucleotides (ASOs) are short synthetic strands of nucleic acid designed to bind specifically to mutant mRNA to normalize protein expression.
Developing a personalized medicine requires meticulous research, laboratory validation, and hospital-based intrathecal administration.
Whole genome sequencing confirmed Archie’s CACNA1A variant. Accepted into the n-Lorem Foundation’s nano-rare discovery pipeline.
Scientists synthesize candidate ASO sequences and test them in cell models derived from Archie’s own stem cells to find the best candidate.
Filing an Investigational New Drug (IND) application with the FDA for patient-specific approval.
Intrathecal administration of the ASO therapy at a specialized pediatric neurology center, followed by clinical evaluation.
While n-Lorem generously absorbs the discovery and synthesis cost of the ASO molecule, the family is responsible for hospital administration, specialized neurological monitoring, biomarker studies, and travel to clinical centers.
Donations to Archie’s fund support his treatment, clinical visits, and therapy needs.
Support Archie TodayFollow along as we post milestones, clinical progress reports, and family moments.
Loading updates…
Every gift goes to Archie’s fund at Rare Village Foundation
Donations are processed securely by Rare Village Foundation, which manages Archie’s fund. You can choose any amount on their donation page, and every gift, large or small, helps put on Archie’s armor.
You’ll be taken to Rare Village’s secure donation page.
Reach out directly to Archie’s family